NVAX Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Partner Ecosystem ExpansionA broad partner network can diversify commercialization, validate Matrix-M across multiple programs, and create future milestone and royalty opportunities. This reduces reliance on Novavax funding every program internally, although conversion and execution remain important.
Partner Revenue GrowthStrong growth in partner-related revenue supports a more asset-light monetization model and demonstrates commercial value for Novavax’s platform. If sustained, licensing and supply income can provide recurring revenue beyond direct vaccine sales.
Structural Cost ReductionLower operating costs improve the company’s ability to extend its runway and convert partnership revenue into cash flow. The multi-year reduction plan, including lower 2028 R&D and SG&A guidance, provides operating leverage if revenue stabilizes.
Bears Say
Negative Equity And Solvency PressurePersistent negative equity indicates accumulated financial losses and weak solvency optics. It can constrain financing flexibility, increase dependence on partners or creditors, and leave the company more exposed if planned revenue or funding events are delayed.
Persistent Cash BurnSustained negative operating and free cash flow means the business is not yet self-funding its operations. Continued dependence on partner payments, financing, or asset monetization could limit strategic flexibility if inflows arrive later than expected.
Low Direct Product SalesMinimal direct product revenue leaves Novavax dependent on partners to commercialize its principal marketed vaccine and convert pipeline programs. This reduces control over pricing, distribution and customer relationships while exposing revenue to partner execution and demand decisions.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Currently, no data Available
What is Novavax’s market cap?
Novavax’s market cap is CHF1.22B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.308 by $0.049.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.19.
How many shares outstanding does Novavax have?
Currently, no data Available
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.308. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in CH:NVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF11.81 (― Downside)
CHF11.81 (― Downside)
Blogger Sentiment
Bullish
CH:NVAX Sentiment 94%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
-2.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.50%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
NVAX Company Deck
NVAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong strategic progress: rapid expansion of partner collaborations, material partner-driven revenue growth, improved cash position and meaningful reductions in operating costs. Management showcased encouraging preclinical data (notably for a prioritized C. difficile asset) and reiterated 2026 guidance while outlining a credible path to non-GAAP profitability by 2028. Near-term challenges include a large YoY revenue decline driven by a prior-period noncash item, modest direct product sales, continued reliance on partners to convert MTAs to licensed programs and some near-term expense support for partners. On balance, the highlights—particularly partnership momentum, partner-revenue growth, cash runway and cost reductions—substantially outweigh the lowlights, though execution and timing risks remain.View all CH:NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$11.81
Vir Biotechnology
―
Oric Pharmaceuticals
―
―
AbCellera Biologics
―
Sana Biotechnology
―